Skip to main content
SpringerLink
Log in

Metastatic sarcoma: tailored strategies for a heterogeneous disease

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Soft tissue sarcomas are rare diseases that encompass a very heterogeneous group of tumors with diverse pathology and clinically overlapping characteristics. Although some treatment options may be used across different subtypes, each is characterized by specific features and may benefit more from specific approaches. In such a rare and peculiar group of diseases, it is rather important to define the best strategy to prolong survival and improve the quality of life of the patients. Although anthracycline-based chemotherapy remains a milestone in the first-line setting, in recent years novel targeted and immune therapies have been developed and more tailored strategies are possible. For these reasons, every case should be discussed in a multidisciplinary board that includes all specialists involved in the treatment of these patients, since the combination of systemic and local treatments can often be proposed. In this short review, we present the state of the art and offer future perspectives for the management of soft tissue sarcomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fletcher CD, Hogendoorn PC, Mertens F, Bridge J. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC press; 2013.

    Google Scholar 

  2. Burningham Z, Hashibe M, Spector L, et al. The epidemiology of sarcoma. Clin Sarcoma Res. 2012;2:14. https://doi.org/10.1186/2045-3329-2-14.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Chao C, Al-Saleem T, Brooks JJ, et al. Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann Surg Oncol. 2001;8(3):260–7. https://doi.org/10.1007/s10434-001-0260-9.

    Article  CAS  PubMed  Google Scholar 

  4. Pakos EE, Goussia AC, Tsekeris PG, Papachristou DJ, Stefanou D, Agnantis NJ. Expression of vascular endothelial growth factor and its receptor, KDR/Flk‑1, in soft tissue sarcomas. Anticancer Res. 2005;25(5):3591–6.

    CAS  PubMed  Google Scholar 

  5. Quesada J, Amato R. The molecular biology of soft-tissue sarcomas and current trends in therapy. Sarcoma. 2012; https://doi.org/10.1155/2012/849456.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Frezza AM, Stacchiotti S, Gronchi A. Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new. BMC Med. 2017;15(1):109. https://doi.org/10.1186/s12916-017-0872-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Benjamin RS, Wiernik PH, Bachur NR. Adriamycin: a new effective agent in the therapy of disseminated sarcomas. Med Pediatr Oncol. 1975;1(1):63–76.

    Article  CAS  Google Scholar 

  8. Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol. 1987;5(6):840–50.

    Article  CAS  Google Scholar 

  9. Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15:415–23.

    Article  CAS  Google Scholar 

  10. Lorigan P, Verweij J, Papai Z, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 2007;25:3144–50.

    Article  CAS  Google Scholar 

  11. Wilding CP, Elms ML, Judson I, et al. The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib. Expert Rev Anticancer Ther. 2019;19(11):971–91. https://doi.org/10.1080/14737140.2019.1686979.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A. 2006;103(3):690–5.

    Article  CAS  Google Scholar 

  13. Cupp JS, Miller MA, Montgomery KD, et al. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am J Surg Pathol. 2007;31(6):970–6.

    Article  Google Scholar 

  14. Verspoor FGM, Mastboom MJL, Hannink G, et al. Long-term efficacy of imatinib mesylate in patients with advanced tenosynovial giant cell tumor. Sci Rep. 2019;9(1):14551. https://doi.org/10.1038/s41598-019-51211-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Tap WD, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019;394(10197):478–87.

    Article  CAS  Google Scholar 

  16. Lamb YN. Pexidartinib: first approval. Drugs. 2019;79:1805–12. https://doi.org/10.1007/s40265-019-01210-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Navarrete-Dechent C, Mori S, Barker CA, Dickson MA, Nehal KS. Imatinib treatment for locally advanced or metastatic dermatofibrosarcoma protuberans: a systematic review. JAMA Dermatol. 2019;155(3):361–9. https://doi.org/10.1001/jamadermatol.2018.4940.

    Article  PubMed  Google Scholar 

  18. Stacchiotti S, Tortoreto M, Baldi GG, et al. Preclinical and clinical evidence of activity of pazopanib in soft fibrous tumour. Eur J Cancer. 2014;50:3021–8.

    Article  CAS  Google Scholar 

  19. Stacchiotti S, Negri T, Libertini M, et al. Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol. 2012;23:3171–9.

    Article  CAS  Google Scholar 

  20. Sardaro A, Bardoscia L, Petruzzelli MF, Portaluri M. Epithelioid hemangioendothelioma: an overview and update on a rare vascular tumor. Oncol Rev. 2014;8(2):259. https://doi.org/10.4081/oncol.2014.259.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Cousin S, Le Loarer F, Crombé A, et al. Epithelioid hemangioendothelioma. Bull Cancer. 2019;106(1):73–83. https://doi.org/10.1016/j.bulcan.2018.11.004.

    Article  PubMed  Google Scholar 

  22. Rosenberg A, Agulnik M. Epithelioid hemangioendothelioma: update on diagnosis and treatment. Curr Treat Options Oncol. 2018;19:19. https://doi.org/10.1007/s11864-018-0536-y.

    Article  PubMed  Google Scholar 

  23. Kollár A, Jones RL, Stacchiotti S, et al. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol 2017; 56(1):88–92. https://doi.org/10.1080/0284186X.2016.1234068.

  24. Chevreau C, Le Cesne A, Ray-Coquard I, et al. Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group. Cancer. 2013;119:2639–44.

    Article  CAS  Google Scholar 

  25. Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013;24:257–63.

    Article  CAS  Google Scholar 

  26. Radzikowska E, Szczepulska-Wójcik E, Chabowski M, et al. Pulmonary epithelioid haemangioendothelioma—interferon 2‑alpha treatment—case report. Pneumonol Alergol Pol. 2008;76(4):281–5.

    PubMed  Google Scholar 

  27. Stacchiotti S, Provenzano S, Dagrada G, et al. Sirolimus in advanced epithelioid hemangioendothelioma: a retrospective case-series analysis from the Italian rare cancer network database. Ann Surg Oncol. 2016;23:2735–44. https://doi.org/10.1245/s10434-016-5331-z.

    Article  PubMed  Google Scholar 

  28. Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol. 2010;28(5):835–40. https://doi.org/10.1200/JCO.2009.25.2981.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Benson C, Vitfell-Rasmussen J, Maruzzo M, et al. A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience. Anticancer Res. 2014;34(7):3663–8.

    PubMed  Google Scholar 

  30. Singhi EK, Moore DC, Muslimani A. Metastatic soft tissue sarcomas: a review of treatment and new pharmacotherapies. P T. 2018;43(7):410–29.

    PubMed  PubMed Central  Google Scholar 

  31. Meyer M, Seetharam M. First-line therapy for metastatic soft tissue sarcoma. Curr Treat Options Oncol. 2019;20:6. https://doi.org/10.1007/s11864-019-0606-9.

    Article  PubMed  Google Scholar 

  32. Lee SH, Chang MH, Baek KK, et al. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and STS patients. Oncology. 2011;80:257–61.

    Article  CAS  Google Scholar 

  33. van Oosterom AT, Mouridsen HT, Nielsen OS, et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first-and second-line chemotherapy in advanced STS patients. Eur J Cancer. 2002;38:2397–406.

    Article  Google Scholar 

  34. Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer. 1994;73:2506–11. https://doi.org/10.1002/1097-0142(19940515)73:10.

    Article  CAS  PubMed  Google Scholar 

  35. Duffaud F, Pautier P, Bui B, et al. A pooled analysis of the final results of the two randomized phase II studies comparing Gemcitabine (G) vs Gemcitabine + Docetaxel (G + D) in patients (pts) with metastatic/relapsed leiomyosarcoma (LMS). Milan: European Society for Medical Oncology; 2010.

    Google Scholar 

  36. Stacchiotti S, Palassini E, Sanfilippo R, et al. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. Ann Oncol. 2012;23:501–8. https://doi.org/10.1093/annonc/mdr066.

    Article  CAS  PubMed  Google Scholar 

  37. Bui-Nguyen B, Butrynski JE, Penel N, et al. A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial. Eur J Cancer. 2015;51:1312–20. https://doi.org/10.1016/j.ejca .2015.03.023.

    Article  CAS  Google Scholar 

  38. Forni C, Minuzzo M, Virdis E, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009;8:449–57.

    Article  CAS  Google Scholar 

  39. Di Giandomenico S, Frapolli R, Bello E, et al. Mode of action of trabectedin in myxoid liposarcomas. Oncogene. 2014;33:5201–10. https://doi.org/10.1038/onc.2013.462.

    Article  CAS  PubMed  Google Scholar 

  40. Schoffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387:1629–37. https://doi.org/10.1016/S0140-6736(15)01283-0.

    Article  CAS  PubMed  Google Scholar 

  41. Dybdal-Hargreaves NF, Risinger AL, Mooberry SL. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clin Cancer Res. 2015;21:2445–52.

    Article  CAS  Google Scholar 

  42. Yoshida T, Ozawa Y, Kimura T, et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer. 2014;110:1497–505.

    Article  CAS  Google Scholar 

  43. Laughney AM, Kim E, Sprachman MM, et al. Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin. Sci Transl Med. 2014;6(261):261ra152. https://doi.org/10.1126/scitranslmed.3009318.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. D’Angelo SP, Munhoz RR, Kuk D, et al. Outcomes of systemic therapy for patients with metastatic angiosarcoma. Oncology. 2015;89(4):205–14. https://doi.org/10.1159/000381917.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Dickson MA, D’Adamo DR, Keohan ML, et al. Phase II trial of gemcitabine and docetaxel with bevacizumab in soft tissue sarcoma. Sarcoma. 2015;2015:532478. https://doi.org/10.1155/2015/532478.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Cao J, Wang J, He C, Fang M. Angiosarcoma: a review of diagnosis and current treatment. Am J Cancer Res. 2019;9(11):2303–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Apice G, Pizzolorusso A, Di Maio M, et al. Confirmed activity and tolerability of weekly paclitaxel in the treatment of advanced angiosarcoma. Sarcoma. 2016;2016:6862090. https://doi.org/10.1155/2016/6862090.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Penel N, Italiano A, Ray-coquard I, et al. Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome. Ann Oncol. 2012;23(2):517–23. https://doi.org/10.1093/annonc/mdr138.

    Article  CAS  PubMed  Google Scholar 

  49. Fata F, O’Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999;86(10):2034–7. https://doi.org/10.1002/(sici)1097-0142(19991115)86:10.

    Article  CAS  PubMed  Google Scholar 

  50. Schlemmer M, Reichardt P, Verweij J, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer. 2008;44(16):2433–6. https://doi.org/10.1016/j.ejca.2008.07.037.

    Article  CAS  PubMed  Google Scholar 

  51. Penel N, Bui BN, Bay J‑O, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol. 2008;26(32):5269–74. https://doi.org/10.1200/jco.2008.17.3146.

    Article  CAS  PubMed  Google Scholar 

  52. Italiano A, Cioffi A, Penel N, et al. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer. 2012;118(13):3330–6. https://doi.org/10.1002/cncr.26599.

    Article  CAS  PubMed  Google Scholar 

  53. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86.

    Article  Google Scholar 

  54. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):271–82. https://doi.org/10.1016/S1470-2045(19)30691-6.

    Article  CAS  PubMed  Google Scholar 

  55. Hong DS, Bauer TM, Lee JJ, et al. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol. 2019;30(2):325–31. https://doi.org/10.1093/annonc/mdy539.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Shang H, Braggio D, Lee YJ, et al. Targeting the Notch pathway: a potential therapeutic approach for desmoid tumors. Cancer. 2015;121(22):4088–96. https://doi.org/10.1002/cncr.29564.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Kummar S, O’Sullivan Coyne G, Do KT, et al. Clinical activity of the γ‑secretase inhibitor PF-03084014 in adults with desmoid tumors (aggressive fibromatosis). J Clin Oncol. 2017;35(14):1561–9. https://doi.org/10.1200/JCO.2016.71.1994.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Messersmith WA, Shapiro GI, Cleary JM, et al. A phase I, dose-finding study in patients with advanced solid malignancies of the oral γ‑secretase inhibitor PF-03084014. Clin Cancer Res. 2015;21:60–7. https://doi.org/10.1158/1078-0432.CCR-14-0607.

    Article  CAS  PubMed  Google Scholar 

  59. Reichardt P, Lindner T, Pink D, et al. Chemotherapy in alveolar soft part sarcomas. What do we know? Eur J Cancer. 2003;39:1511–6.

    Article  CAS  Google Scholar 

  60. Agulnik M, Tannir NM, Pressey JG, et al. A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma. J Clin Oncol. 2016;34(suppl):abstr TPS11071.

    Article  Google Scholar 

  61. D’Angelo SP, Mahoney MR, Van Tine BA, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19(3):416–26. https://doi.org/10.1016/S1470-2045(18)30006-8.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Tawbi HAH, Burgess M, Crowley J, et al. Safety and efficacy of PD‑1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): results of SARC028—a multicenter phase II study. J Clin Oncol. 2016;34(suppl):abstr 11006.

    Article  Google Scholar 

  63. Paoluzzi L, Cacavio A, Ghesani M, et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res. 2016;6:24. https://doi.org/10.1186/s13569-016-0064-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Pollack S, Redman MW, Wagner M, et al. A phase I/II study of pembrolizumab (Pem) and doxorubicin (Dox) in treating patients with metastatic/unresectable sarcoma. J Clin Oncol. 2019;37(15_suppl):11009. https://doi.org/10.1200/JCO.2019.37.15_suppl.11009.

    Article  Google Scholar 

  65. Gordon EM, Chua-Alcala VS, Kim K, et al. SAINT: results of a phase 1/2 study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma. J Clin Oncol. 2019;37(15_suppl):11016. https://doi.org/10.1200/JCO.2019.37.15_suppl.11016.

    Article  Google Scholar 

  66. Wilky BA, Trucco MM, Subhawong TK, et al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncol. 2019;20(6):837–48. https://doi.org/10.1016/S1470-2045(19)30153-6.

    Article  CAS  PubMed  Google Scholar 

  67. Kelly CM, Antonescu CR, Bowler T, et al. Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab: a phase 2 clinical trial. JAMA Oncol. 2020; https://doi.org/10.1001/jamaoncol.2019.6152.

    Article  PubMed  Google Scholar 

  68. Iura K, Maekawa A, Kohashi K, et al. Cancer-testis antigen expression in synovial sarcoma: NY-ESO‑1, PRAME, MAGEA4 and MAGEA1. Hum Pathol. 2017;61:130–9. https://doi.org/10.1016/j.humpath.2016.12.006.

    Article  CAS  PubMed  Google Scholar 

  69. Chung PWM, Deheshi BM, Ferguson PC, et al. Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma. Cancer 2009; 115:3254–61. https://doi.org/10.1002/cncr.24375.

  70. Dudek W, Schreiner W, Mykoliuk I, Higaze M, Sirbu H. Pulmonary metastasectomy for sarcoma-survival and prognostic analysis. J Thorac Dis. 2019;11(8):3369–76. https://doi.org/10.21037/jtd.2019.08.10.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Miner TJ, Brennan MF, Jaques DP. A prospective, symptom related, outcomes analysis of 1022 palliative procedures for advanced cancer. Ann Surg. 2004;240:719–26. https://doi.org/10.1097/01.sla.0000141707.09312.dd. discussion 726.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cancer Medicine, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale Tumori, Milan, Italy

    Massimiliano Grassi & Andrea Spagnoletti

  2. Medical Oncology Unit 1, Ospedale Policlinico San Martino IRCCS, University of Genoa, L.go R. Benzi 10, 16132, Genoa, Italy

    Massimiliano Grassi & Alberto Puccini MD

Authors
  1. Massimiliano Grassi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Spagnoletti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alberto Puccini MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alberto Puccini MD.

Ethics declarations

Conflict of interest

M. Grassi, A. Spagnoletti, and A. Puccini declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grassi, M., Spagnoletti, A. & Puccini, A. Metastatic sarcoma: tailored strategies for a heterogeneous disease. memo 13, 179–184 (2020). https://doi.org/10.1007/s12254-020-00598-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-020-00598-w

Keywords

Search

Navigation